<DOC>
	<DOCNO>NCT02353741</DOCNO>
	<brief_summary>This single-arm phase II study aim study efficacy possible first line treatment combine epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) concurrent thoracic radiation therapy stage IV non-small cell lung cancer ( NSCLC ) active EGFR mutation , well assess PFS , OS , tumor response , etc . verify new combinational therapy benefit short-term long-term survival patient advance NSCLC .</brief_summary>
	<brief_title>Concurrent EGFR-TKIs Thoracic Radiation Therapy Active EGFR Mutation 1st Line Treatment Stage IV NSCLC</brief_title>
	<detailed_description>Based NCCN guideline epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) erlotinib , gefitinib icotinib first line treatment advance Non-Small Cell Lung Cancer ( NSCLC ) , efficacy EGFR-TKIs combination thoracic radiotherapy first line treatment stage IV NSCLC active EGFR mutation remain unknown . In single-arm phase II trial , chose subject stage IV harbor active EGFR mutation , treat EGFR-TKIs combined radiation therapy . The primary endpoint 1-year rate progression-free survival second endpoint overall survival ( OS ) , objective response rate toxic side effect . By evaluate , expect find evidence combination therapy benefit short-term long-term survival patient . Meanwhile , via stratification analysis tumor biomarker immune index , obtain evidence benefit comprehensive individual treatment advance NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . ECOG performance status≤2； 2 . Cytologically pathologically confirm stage IV NSCLC ( control pleural effusion eligible ) active EGFR mutation ; 3 . Estimated survival time 3 month ; 4 . Age old 18 year 75 year ; 5 . Adequate bone marrow , hepatic , renal function ; AST ALT≤2.5 time high reference value associate hepatic metastasis , ≤5 time hepatic metastasis occur ; 6 . Without history therapy primary metastatic disease ; 7 . With pleural effusion control ; 8 . Asymptomatic bone metastasis without treatment ; 9 . Based fusion image 4DCT MIP sketch tumor lymph node , limit mean lung dose : V20≤25 % ，V30≤18 % ，MLD≤14Gy，V5≤60 % ; 10 . M1a M1b metastases , number distant lesion ≤10； 11 . Voluntary participate clinical trial sign consent form . 1 . Patients serious functional damage important organ ; 2 . Patients diagnose adequately malignant tumor ; 3 . Pregnant lactating woman ; 4 . Patients active period acute chronic infectious disease ; 5 . Patients allergic drug people allergy ; 6 . With brain metastasis ; 7 . With bone metastasis need radiotherapy ; 8 . Patients participate clinical trial concurrently ; 9 . Uncontrolled pleural effusion may intervene radiotherapy primary tumor lung ; 10 . The number distant lesions＞10； 11 . Patients consider eligible trial evaluation investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>